Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 13/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384844 | 0.86 | MMP13 (0.47) | SLC6A3DPP4MAPK1 | |
| SCHEMBL23211739 | 0.84 | DPP4 (0.38) | SLC6A3DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL23211866 | 0.79 | SLC6A2 (0.36) | SLC6A3 | |
| SCHEMBL21381650 | 0.79 | SLC6A3 (0.51) | SLC6A3DPP4DPP7DPP8DPP9 | |
| SCHEMBL23211803 | 0.78 | MGLL (0.58) | MGLL | |
| SCHEMBL21390552 | 0.78 | MGLL (0.58) | MGLL | |
| SCHEMBL25057334 | 0.78 | SLC6A3 (0.34) | SLC6A3DPP4DPP7DPP8DPP9 | |
| SCHEMBL21381594 | 0.72 | MMP13 (0.47) | DPP4LMNAMAPK1 | |
| SCHEMBL23211817 | 0.72 | MMP13 (0.47) | DPP4LMNAMAPK1 | |
| SCHEMBL21382145 | 0.70 | SLC6A3 (0.41) | SLC6A3DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SLC6A3 4431/4885DPP4 542/4885DPP7 730/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SLC6A3 4431/4885DPP4 542/4885DPP7 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.